The objective of this study was to observe and analyze the clinical value and nursing effect of ß- humanchorionic gonadotropin and progesterone monitoring on the treatment of ectopic pregnancy withmethotrexate combined with mifepristone. One hundred and eighty patients with ectopic pregnancy wereincluded in the study, all of whom were treated with methotrexate combined with mifepristone tablets.According to the treatment results, they were divided into treatment success group and the treatment failuregroup, each containing with 90 cases. The levels of ß- human chorionic gonadotropin and progesteronein the two groups were compared. Of the 180 patients, 168 were cured successfully, 12 were failed, andthe success rate and failure rate were 93.33% and 6.67%, respectively. After treatment, serum ß- humanchorionic gonadotropin and progesterone levels in the successful group decreased more significantly ascompared with that before treatment, p<0.05. When the levels of ß-human chorionic gonadotropin andprogesterone were increased, the success rate of methotrexate combined with mifepristone tablets showeda decreasing trend, p<0.05. When the maximum diameter value of pelvic effusion was increased, thesuccess rate of conservative treatment with methotrexate combined with mifepristone tablets showeda decreasing trend, p<0.05. The risk factors that affect the success rate of methotrexate combined withmifepristone tablets are ß-human chorionic gonadotropin level and progesterone level. To concludeß- human chorionic gonadotropin and progesterone monitoring is a key step for treatment of ectopicpregnancy. Combined monitoring is of great significance in predicting the success of conservativetreatment of ectopic pregnancy